83.84

0.28% 0.23

After Hours: 83.84

Gilead Sciences Inc (GILD)

Overview News Price History Option Chain Financials Why GILD Down? Discussions Forecast Stock Split Dividend History

Gilead Sciences Inc stock is traded at $83.84, with a volume of 4.97M. It is up +0.28% in the last 24 hours and up +6.13% over the past month. Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Previous Close:

$83.61

Open:

$83.15

24h Volume:

4.97M

Relative Volume:

0.81

Market Cap:

$104.18B

Revenue:

$27.80B

Net Income/Loss:

$1.05B

P/E Ratio:

19.27

EPS:

4.35

Net Cash Flow:

$6.90B

1W Performance:

-0.18%

1M Performance:

+6.13%

6M Performance:

+14.46%

1Y Performance:

+11.88%

1-Day Range:

$83.14

$84.25

1-Week Range:

$81.83

$84.33

52-Week Range:

$62.07

$87.86

Gilead Sciences Inc Stock (GILD) Company Profile

Name

Gilead Sciences Inc

Sector

Healthcare (1203)

Industry

Drug Manufacturers - General (17)

Phone

(650) 574-3000

Address

333 LAKESIDE DR, FOSTER CITY, CA

Employee

18,000

Twitter

@GileadSciences

Next Earnings Date

2024-08-08

Latest SEC Filings

GILD's Discussions on Twitter

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-09-23	Initiated	Deutsche Bank	Hold
Sep-08-23	Upgrade	BofA Securities	Neutral → Buy
Sep-06-23	Initiated	HSBC Securities	Reduce
Jul-24-23	Reiterated	Barclays	Equal Weight
May-16-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Apr-28-23	Resumed	Piper Sandler	Overweight
Jan-03-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Dec-13-22	Resumed	BofA Securities	Neutral
Dec-09-22	Downgrade	DZ Bank	Buy → Hold
Oct-31-22	Upgrade	Barclays	Underweight → Equal Weight
Oct-28-22	Reiterated	BMO Capital Markets	Market Perform
Oct-28-22	Reiterated	Cowen	Outperform
Oct-28-22	Reiterated	JP Morgan	Overweight
Oct-28-22	Reiterated	Jefferies	Buy
Oct-28-22	Upgrade	Piper Sandler	Neutral → Overweight
Oct-28-22	Reiterated	RBC Capital Mkts	Outperform
Oct-28-22	Upgrade	Truist	Hold → Buy
Oct-28-22	Reiterated	Wells Fargo	Equal Weight
Oct-04-22	Upgrade	JP Morgan	Neutral → Overweight
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral
May-23-22	Initiated	SVB Leerink	Mkt Perform
Feb-28-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Feb-02-22	Reiterated	BMO Capital Markets	Outperform
Feb-02-22	Reiterated	BofA Securities	Neutral
Feb-02-22	Reiterated	RBC Capital Mkts	Outperform
Feb-02-22	Reiterated	Truist	Hold
Feb-02-22	Reiterated	Wells Fargo	Equal Weight
Jan-28-22	Upgrade	Argus	Hold → Buy
Jan-06-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-09-21	Resumed	Wells Fargo	Equal Weight
Dec-06-21	Initiated	Goldman	Neutral
Nov-19-21	Upgrade	BMO Capital Markets	Market Perform → Outperform
Nov-19-21	Resumed	Piper Sandler	Neutral
Oct-20-21	Resumed	Cowen	Outperform
Jul-30-21	Reiterated	BMO Capital Markets	Market Perform
Jul-30-21	Reiterated	RBC Capital Mkts	Outperform
Apr-01-21	Upgrade	Bernstein	Mkt Perform → Outperform
Mar-30-21	Upgrade	Redburn	Neutral → Buy
Jan-19-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-04-21	Upgrade	Guggenheim	Neutral → Buy
Nov-03-20	Resumed	Morgan Stanley	Equal-Weight
Oct-28-20	Initiated	UBS	Neutral
Sep-30-20	Resumed	Jefferies	Buy
Sep-15-20	Upgrade	Maxim Group	Hold → Buy
Jul-31-20	Reiterated	Credit Suisse	Neutral
Jul-31-20	Reiterated	Morgan Stanley	Equal-Weight
Jul-31-20	Reiterated	Piper Sandler	Overweight
Jul-31-20	Reiterated	RBC Capital Mkts	Outperform
Jul-31-20	Reiterated	SunTrust	Hold
Jul-31-20	Reiterated	Wells Fargo	Equal Weight
Jul-20-20	Upgrade	Credit Suisse	Underperform → Neutral
Jun-03-20	Upgrade	SVB Leerink	Mkt Perform → Outperform
May-26-20	Upgrade	SunTrust	Sell → Hold
May-01-20	Downgrade	JP Morgan	Overweight → Neutral
May-01-20	Downgrade	Raymond James	Outperform → Mkt Perform
May-01-20	Downgrade	SunTrust	Hold → Sell
Apr-27-20	Downgrade	UBS	Buy → Neutral
Apr-20-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
Apr-20-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-17-20	Downgrade	CFRA	Hold → Sell

View All

Gilead Sciences Inc Stock (GILD) Latest News

04:44 AM

Gilead Sciences Inc. stock rises Monday, still underperforms market - MarketWatch

04:44 AM

11:11 AM

New Report Shows Every Country in the World Must Do More to End the HIV Epidemic - Gilead Sciences

11:11 AM

04:34 AM

Marshall Wace LLP Makes New $8.27 Million Investment in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

04:34 AM

04:13 AM

Gilead Sciences' SWOT analysis: HIV leader faces oncology hurdles, seeks liver disease growth - Investing.com India

04:13 AM

03:00 AM

Gilead Sciences Trying To Close In On Key Technical Benchmark - Investor's Business Daily

03:00 AM

Sep 29, 2024

Doheny Asset Management CA Invests $2.69 Million in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Sep 29, 2024

Sep 28, 2024

Lighthouse Investment Partners LLC Invests $3.88 Million in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Sep 28, 2024

Sep 27, 2024

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Acquired by Legal & General Group Plc - MarketBeat

Sep 27, 2024

Sep 26, 2024

Research Scholars Program - Gilead Sciences

Sep 26, 2024

Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 26, 2024

Championing HIV Services for LGBTQ+ Youth - CSRwire.com

Sep 26, 2024

FY2024 Earnings Estimate for Gilead Sciences, Inc. (NASDAQ:GILD) Issued By Cantor Fitzgerald - MarketBeat

Sep 26, 2024

Deerfield Management Company L.P. Series C Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Sep 26, 2024

Sep 25, 2024

FTC weighs in on reverse-payment generic delay case involving Gilead, Teva - MSN

Sep 25, 2024

FTC weighs in on reverse-payment generic delay case involving Gilead, Teva - Seeking Alpha

Sep 25, 2024

Gilead dominates Asian patient groups' drugmaker reputation rankings - FiercePharma

Sep 25, 2024

Gilead recalls one lot of COVID-19 drug Veklury due to presence of glass particle in vial - FiercePharma

Sep 25, 2024

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Has $16.39 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Sep 25, 2024

Anti-retroviral Drugs Market to hit USD 42.5 billion by 2032, says Global Market Insights Inc. - GlobeNewswire Inc.

Sep 25, 2024

Sep 24, 2024

Gilead Sciences (GILD) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance

Sep 24, 2024

Gilead Sciences Recalls One Lot of Veklury (Remdesivir) Due to Glass Particle Contamination - Franklin County Free Press

Sep 24, 2024

Epoch Investment Partners Inc. Reduces Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Sep 24, 2024

Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles - AOL

Sep 23, 2024

Notable Monday Option Activity: GWW, DJT, LLY - Nasdaq

Sep 23, 2024

Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles - Yahoo Finance

Sep 23, 2024

Gilead Claims Twice-Annual Injection Better At Preventing HIV Than Daily PrEP Pill - AboutLawsuits.com

Sep 23, 2024

AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug - Investor's Business Daily

Sep 23, 2024

Gilead shares stable as AstraZeneca trial fails to impress - Investing.com India

Sep 23, 2024

GILD: 3 Biotech Stocks to Watch as FDA Approvals Roll In - StockNews.com

Sep 23, 2024

Barclays on Gilead Sciences (GILD): 'Modest positive read-through for Trodelvy positioning in 2L+ HR/Her2- breast cancer' - StreetInsider.com

Sep 23, 2024

Gilead shares hold firm as competitor's drug falls short in trial - Investing.com India

Sep 23, 2024

Bank of Montreal Can Boosts Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Sep 23, 2024

Jefferies on Gilead Sciences (GILD): 'Competitor Dato surprise setback in breast cancer, new incremental (+) for GILD' - StreetInsider.com

Sep 23, 2024

Sep 22, 2024

Sompo Asset Management Co. Ltd. Has $336,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD) - Defense World

Sep 22, 2024

Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Frank Rimerman Advisors LLC - MarketBeat

Sep 22, 2024

Sep 21, 2024

Ameritas Investment Partners Inc. Lowers Holdings in Eli Lilly and Company (NYSE:LLY) - Defense World

Sep 21, 2024

Gilead Sciences, Verizon Communications And ManpowerGroup Are Winners For Passive Income - Yahoo Finance

Sep 21, 2024

3 Dirt Cheap Stocks to Buy Right Now - The Motley Fool

Sep 21, 2024

Thrivent Financial for Lutherans Buys 1,262,193 Shares of Gilead Sciences, Inc. (NASDAQ:GILD) - MarketBeat

Sep 21, 2024

Sep 20, 2024

GM Advisory Group LLC Boosts Stake in Eli Lilly and Company (NYSE:LLY) - Defense World

Sep 20, 2024

Gilead Sciences Unusual Options Activity For September 20 - Benzinga

Sep 20, 2024

Injectable PrEP continues to show promising results - Gay City News

Sep 20, 2024

Gilead taps Korea's Yuhan to supply HIV drug ingredients in $81M deal - FiercePharma

Sep 20, 2024

Gilead chalks up another win in fake HIV meds lawsuit - SecuringIndustry.com

Sep 20, 2024